Regenesis Biomedical Inc. is a medical device company based in Scottsdale, Arizona, founded in 1996. The company specializes in the research, design, manufacture, and sale of noninvasive regenerative medicine products aimed at alleviating pain and restoring health. Its primary product, the Provant Therapy System, utilizes an electromagnetic field to reduce pain and swelling in skin and soft tissues following surgical procedures. The company serves a diverse clientele that includes healthcare facilities, acute and long-term care hospitals, skilled nursing facilities, rehabilitation centers, outpatient clinics, and home healthcare providers, all catering to patients under physician orders. Through its innovative approach, Regenesis Biomedical strives to enhance the quality of life for patients experiencing post-operative discomfort.
HTG Molecular Diagnostics is a leading provider of molecular-based technology
solutions for gene expression profiling, miRNA, siRNA and mRNA measurement for
translational medicine and diagnostic applications. The Company's qNPA molecular technology platform is well-suited for reliably detecting small, yet important, changes in gene expression levels in a variety of sample types. Privately-held HTG is based Tucson, Arizona.
HTG Molecular Diagnostics is a leading provider of molecular-based technology
solutions for gene expression profiling, miRNA, siRNA and mRNA measurement for
translational medicine and diagnostic applications. The Company's qNPA molecular technology platform is well-suited for reliably detecting small, yet important, changes in gene expression levels in a variety of sample types. Privately-held HTG is based Tucson, Arizona.
Regenesis Biomedical Inc. is a medical device company based in Scottsdale, Arizona, founded in 1996. The company specializes in the research, design, manufacture, and sale of noninvasive regenerative medicine products aimed at alleviating pain and restoring health. Its primary product, the Provant Therapy System, utilizes an electromagnetic field to reduce pain and swelling in skin and soft tissues following surgical procedures. The company serves a diverse clientele that includes healthcare facilities, acute and long-term care hospitals, skilled nursing facilities, rehabilitation centers, outpatient clinics, and home healthcare providers, all catering to patients under physician orders. Through its innovative approach, Regenesis Biomedical strives to enhance the quality of life for patients experiencing post-operative discomfort.
AmpliMed Corporation focuses on the development of small-molecule oncology drugs. Its products include Amplimexon, a small molecule that causes cancer cells to stop dividing and ultimately to die; Amplizone that has demonstrated efficacy in the treatment of solid tumors in animal tumor models; and benzimidazole Series: benzimidazole analog small molecules that expressed tubulin binding activity in yeast and mammalian cells. The company’s products are used to treat pancreatic cancer, lung cancer, malignant melanoma, ovarian cancer, and multiple myeloma. AmpliMed Corporation was founded in 1989 and is based in Tucson, Arizona.
HTG Molecular Diagnostics is a leading provider of molecular-based technology
solutions for gene expression profiling, miRNA, siRNA and mRNA measurement for
translational medicine and diagnostic applications. The Company's qNPA molecular technology platform is well-suited for reliably detecting small, yet important, changes in gene expression levels in a variety of sample types. Privately-held HTG is based Tucson, Arizona.
Regenesis Biomedical Inc. is a medical device company based in Scottsdale, Arizona, founded in 1996. The company specializes in the research, design, manufacture, and sale of noninvasive regenerative medicine products aimed at alleviating pain and restoring health. Its primary product, the Provant Therapy System, utilizes an electromagnetic field to reduce pain and swelling in skin and soft tissues following surgical procedures. The company serves a diverse clientele that includes healthcare facilities, acute and long-term care hospitals, skilled nursing facilities, rehabilitation centers, outpatient clinics, and home healthcare providers, all catering to patients under physician orders. Through its innovative approach, Regenesis Biomedical strives to enhance the quality of life for patients experiencing post-operative discomfort.
Carefx's main solution "Fusionfx" helps close information gaps between hospital/IDN CIO and CMIO and healthcare IT departments.
Fusionfx is able to help "synthesize disparate data into clinically relevant, user-centric workflows." The solution aims to connect the data points and make it comprehensive/understandable fo patients, payers, clinicians, and the compliance agencies who seek such information.
HTG Molecular Diagnostics is a leading provider of molecular-based technology
solutions for gene expression profiling, miRNA, siRNA and mRNA measurement for
translational medicine and diagnostic applications. The Company's qNPA molecular technology platform is well-suited for reliably detecting small, yet important, changes in gene expression levels in a variety of sample types. Privately-held HTG is based Tucson, Arizona.
Carefx's main solution "Fusionfx" helps close information gaps between hospital/IDN CIO and CMIO and healthcare IT departments.
Fusionfx is able to help "synthesize disparate data into clinically relevant, user-centric workflows." The solution aims to connect the data points and make it comprehensive/understandable fo patients, payers, clinicians, and the compliance agencies who seek such information.
AmpliMed Corporation focuses on the development of small-molecule oncology drugs. Its products include Amplimexon, a small molecule that causes cancer cells to stop dividing and ultimately to die; Amplizone that has demonstrated efficacy in the treatment of solid tumors in animal tumor models; and benzimidazole Series: benzimidazole analog small molecules that expressed tubulin binding activity in yeast and mammalian cells. The company’s products are used to treat pancreatic cancer, lung cancer, malignant melanoma, ovarian cancer, and multiple myeloma. AmpliMed Corporation was founded in 1989 and is based in Tucson, Arizona.
AmpliMed Corporation focuses on the development of small-molecule oncology drugs. Its products include Amplimexon, a small molecule that causes cancer cells to stop dividing and ultimately to die; Amplizone that has demonstrated efficacy in the treatment of solid tumors in animal tumor models; and benzimidazole Series: benzimidazole analog small molecules that expressed tubulin binding activity in yeast and mammalian cells. The company’s products are used to treat pancreatic cancer, lung cancer, malignant melanoma, ovarian cancer, and multiple myeloma. AmpliMed Corporation was founded in 1989 and is based in Tucson, Arizona.
HTG Molecular Diagnostics is a leading provider of molecular-based technology
solutions for gene expression profiling, miRNA, siRNA and mRNA measurement for
translational medicine and diagnostic applications. The Company's qNPA molecular technology platform is well-suited for reliably detecting small, yet important, changes in gene expression levels in a variety of sample types. Privately-held HTG is based Tucson, Arizona.
AmpliMed Corporation focuses on the development of small-molecule oncology drugs. Its products include Amplimexon, a small molecule that causes cancer cells to stop dividing and ultimately to die; Amplizone that has demonstrated efficacy in the treatment of solid tumors in animal tumor models; and benzimidazole Series: benzimidazole analog small molecules that expressed tubulin binding activity in yeast and mammalian cells. The company’s products are used to treat pancreatic cancer, lung cancer, malignant melanoma, ovarian cancer, and multiple myeloma. AmpliMed Corporation was founded in 1989 and is based in Tucson, Arizona.
Carefx's main solution "Fusionfx" helps close information gaps between hospital/IDN CIO and CMIO and healthcare IT departments.
Fusionfx is able to help "synthesize disparate data into clinically relevant, user-centric workflows." The solution aims to connect the data points and make it comprehensive/understandable fo patients, payers, clinicians, and the compliance agencies who seek such information.
HTG Molecular Diagnostics is a leading provider of molecular-based technology
solutions for gene expression profiling, miRNA, siRNA and mRNA measurement for
translational medicine and diagnostic applications. The Company's qNPA molecular technology platform is well-suited for reliably detecting small, yet important, changes in gene expression levels in a variety of sample types. Privately-held HTG is based Tucson, Arizona.
Sequencia provides processPoint, the only web based, collaborative Product Lifecycle Management (PLM) solution designed specifically for the consumer packaged goods, food and beverage, pharmaceutical, specialty chemical, and related process industries.